Prior Authorization for Biologics: A Complete Guide for Specialists (2026)

Which Biologics Require Prior Authorization?

Virtually all biologic medications require prior authorization from commercial payers, Medicare Advantage plans, and Medicaid managed care. This includes TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), IL-12/23 inhibitors (ustekinumab), JAK inhibitors (tofacitinib, upadacitinib, baricitinib), and integrin inhibitors (vedolizumab, natalizumab).

The introduction of biosimilars has added complexity rather than reducing it. Many payers now mandate biosimilar-first policies, requiring patients to start on a biosimilar adalimumab or infliximab before the reference product will be covered. Some plans have also implemented non-medical switching policies that force stable patients from reference biologics to biosimilars at renewal. Understanding your patient's specific plan formulary is the essential first step before submitting any biologic PA.

Self-administered biologics (subcutaneous injections) typically go through the pharmacy benefit and require pharmacy PA. Provider-administered biologics (IV infusions) often go through the medical benefit and require medical PA — a completely different process with different forms, different reviewers, and different appeal pathways.

Common Denial Reasons for Biologic PAs

The most frequent denial reason for biologic PAs is incomplete step therapy documentation. Payers require evidence that the patient tried and failed conventional therapies before moving to a biologic. For rheumatoid arthritis, this means methotrexate (or another conventional DMARD) at adequate dose for adequate duration. For psoriasis, this often means topical therapies plus phototherapy or a conventional systemic (methotrexate, cyclosporine, acitretin). For inflammatory bowel disease, mesalamine and immunomodulators (azathioprine, 6-MP) are common required steps.

The second most common denial is requesting a non-preferred biologic when a preferred alternative exists. Payer formularies change frequently — sometimes quarterly — and the preferred TNF inhibitor this quarter may not be the same as last quarter. Always verify the current formulary before submitting.

Other frequent denials include missing lab work (TB testing, hepatitis B/C screening, CBC, LFTs are standard requirements for most biologics), incorrect diagnosis coding (using an unspecified ICD-10 code when a specific one is required), and site-of-care restrictions for infused biologics (payers increasingly require home infusion or ambulatory infusion centers over hospital outpatient settings).

Payer-Specific Tips for Biologic Approvals

Each major payer has distinct requirements that generic PA submissions miss. UnitedHealthcare and OptumRx maintain detailed clinical policies for each biologic class; referencing the specific policy number in your submission signals that you have addressed their criteria. Aetna's Clinical Policy Bulletins are publicly available and should be cited by number. Cigna's Coverage Policies often include specific lab thresholds (e.g., DAS28 score cutoffs for RA biologics) that must be documented.

For Medicare Advantage plans, the LCD (Local Coverage Determination) or NCD (National Coverage Determination) governs medical benefit biologics. Cite the LCD number and demonstrate that your patient meets each listed criterion. For Medicaid, preferred drug lists vary by state, and many state Medicaid programs have unique step therapy sequences that differ from commercial plans.

A critical but often overlooked strategy is to pre-populate the PA form with all supporting documentation on the first submission. Attaching lab results, chart notes documenting prior therapy trials, and a brief Letter of Medical Necessity with the initial PA request reduces back-and-forth and dramatically improves first-pass approval rates. Practices that submit "clean" first-pass PAs see approval rates 25-35% higher than those that submit bare-minimum forms.

Biosimilar Mandates and Non-Medical Switching

As of 2026, most major commercial payers have implemented biosimilar-first policies for adalimumab, infliximab, and rituximab. This means new starts on these molecules will typically be directed to the biosimilar version. For patients already stable on a reference biologic, many payers are implementing non-medical switching at renewal — requiring a transition to the biosimilar to maintain coverage.

If non-medical switching poses a clinical risk for your patient (for example, a patient with a history of immunogenicity or infusion reactions, or a patient whose disease is in deep remission after years on the reference product), you can request a medical exception. Document the specific clinical rationale, cite any relevant literature on switching risks in your patient's condition, and reference the payer's own exception policy.

For IBD patients in particular, there is growing evidence that non-medical switching of infliximab may increase immunogenicity risk in certain populations. Citing this evidence in your exception request strengthens the clinical argument for maintaining the reference product.

How RxCheckUp Simplifies Biologic PAs

RxCheckUp is purpose-built for the complexity of biologic prior authorization. The platform identifies the patient's specific plan, pulls the current formulary and preferred biologic for the indication, checks step therapy requirements against documented medication history, and verifies that required labs and screening are complete before submission.

When a PA is denied, RxCheckUp analyzes the denial reason against the payer's medical policy and drafts a targeted appeal that addresses each deficiency. For biosimilar mandates, RxCheckUp can generate medical exception requests with supporting literature. The result: biologic PA approval rates above 85% on first or second submission, compared to industry averages below 70%.